Tianshu Pharmaceutical's Near-term GHG Emission Reduction Target Validated by SBTi

　　Recently, the near-term greenhouse gas (GHG) emission reduction targets of Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutica) have been successfully validated by the Science Based Targets initiative (SBTi). This fully demonstrates the company's determination and confidence in actively responding to climate change and firmly practicing the ESG philosophy, marking a solid step forward for Tianshu Pharmaceutical on the path of low-carbon and sustainable development.

　　Validated by SBTi, Tianshu Pharmaceutical commits to reducing its Scope 1 and Scope 2 GHG emissions by 63% by 2035 compared with the 2024 baseline year, and will continuously monitor and lower its Scope 3 emissions.

　　SBTi is a global initiative jointly launched by the United Nations Global Compact (UNGC), Carbon Disclosure Project (CDP), World Resources Institute (WRI) and World Wildlife Fund (WWF). It aims to help enterprises set science-aligned emission reduction targets to address climate change. Founded in 2015, SBTi has become one of the world's most influential corporate climate action standard systems, providing enterprises with scientific and systematic emission reduction methodologies to advance their low-carbon development.

　　Tianshu Pharmaceutical has deeply integrated the ESG philosophy into its corporate strategy and operations. The company actively implements process optimization, technological innovation, facility and equipment upgrading, and establishes an energy monitoring system to realize real-time feedback on electricity, water and other energy consumption of individual buildings. Through green office initiatives, energy conservation and carbon reduction have been embedded into daily operations. In addition, Tianshu Pharmaceutical extends the sustainable development concept to supply chain management, cutting the absolute GHG emissions generated from purchased goods and services, and collaborates with partners to drive low-carbon development of the supply chain.

　　Tianshu Pharmaceutical will continue to honor its sustainable development commitments, systematically promote ESG development, and explore green development paths in the pharmaceutical industry. While empowering drug R&D and safeguarding human health, the company actively addresses climate challenges and delivers positive impacts on society and the environment. At present, thanks to its solid practices in environmental protection, Tianshu Pharmaceutical has been awarded honors such as Hubei Provincial Green Factory and Hubei Environmental Green Label Enterprise.